fda warning letter compounded semaglutide september 2025 issued 25 letters to telehealth companies for false and misleading claims about GLP-1 products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Beyond the Headlines: FDA Warning

Cardiovascular Disease High blood pressure, elevated cholesterol, arterial inflammation, and increased risk of heart attack and stroke as excess weight strains the cardiovascular system

We are proud to present another edition of our CUE & ANS (Critical Usage of Empiric Antibiotics & Antifungals The New Saviour) scientific initiative

Therefore, the outcomes of extended fasting, particularly in patients with severe obesity, warrant further investigation

The case adds to the growing body of GLP-1 litigation

Side effect management drives a smaller but significant group of switchers

The innovations surveyed here share something important: they address different barriers